figshare
Browse
krnb_a_1422471_sm0677.pdf (377.83 kB)

miR-106b-responsive gene landscape identifies regulation of Kruppel-like factor family

Download (377.83 kB)
journal contribution
posted on 2017-12-29, 13:35 authored by Cody J. Wehrkamp, Sathish Kumar Natarajan, Ashley M. Mohr, Mary Anne Phillippi, Justin L. Mott

MicroRNA dysregulation is a common feature of cancer and due to the promiscuity of microRNA binding this can result in a wide array of genes whose expression is altered. miR-106b is an oncomiR overexpressed in cholangiocarcinoma and its upregulation in this and other cancers often leads to repression of anti-tumorigenic targets. The goal of this study was to identify the miR-106b-regulated gene landscape in cholangiocarcinoma cells using a genome-wide, unbiased mRNA analysis. Through RNA-Seq we found 112 mRNAs significantly repressed by miR-106b. The majority of these genes contain the specific miR-106b seed-binding site. We have validated 11 genes from this set at the mRNA level and demonstrated regulation by miR-106b of 7 proteins. Combined analysis of our miR-106b-regulated mRNA data set plus published reports indicate that miR-106b binding is anchored by G:C pairing in and near the seed. Novel targets Kruppel-like factor 2 (KLF2) and KLF6 were verified both at the mRNA and at the protein level. Further investigation showed regulation of four other KLF family members by miR-106b. We have discovered coordinated repression of multiple members of the KLF family by miR-106b that may play a role in cholangiocarcinoma tumor biology.

Funding

HHS | NIH | National Cancer Institute (NCI), P30CA036727 HHS | NIH | National Institute of General Medical Sciences (NIGMS), P30GM106397 HHS | NIH | National Institute of General Medical Sciences (NIGMS), P20GM103480 This work was supported by the Center for Drug Delivery and Nanomedicine, UNMC, funded by the National Institutes of Health [P20GM103480]. The PI received support from the Fred & Pamela Buffett Cancer Center Support Grant [P30CA036727]. CJW was supported by a UNMC Graduate Student Fellowship. The Advanced Microscopy Core Facility is supported in part by the Cancer Center as well as the Nebraska Center for Cellular Signaling [P30GM106397]. The High-Throughput DNA Sequencing and Genotyping Core Facility receives partial support from the NCRR [1S10RR027754-01, 5P20RR016469, RR018788-08] and the NIGMS [8P20GM103427, P30GM110768]. The authors are solely responsible for the contents of this publication; it does not necessarily represent the official views of the NIH or NIGMS.

History